R

Remix Therapeutics

Biotech firm developing mRNA-degrading therapies

Head of Medical Affairs

Biology & BiotechConfirmed live in the last 24 hours
Full-timeWatertown, MA, USAIn-person

About the Job

Requirements

  • An advanced life science degree is required; an MD or equivalent medical degree is preferred, and a PhD or PharmD is considered.
  • At least 10 years of medical affairs experience and prior leadership of the function are required.
  • Oncology experience is required; solid tumor experience is strongly preferred, and head and neck or salivary gland experience is an advantage.
  • Experience building a Medical Affairs function from an early state, rather than only running an established function, is required.
  • Existing relationships across oncology academic institutions are required.
  • Excellent written and verbal communication skills, including experience authoring or reviewing scientific and medical content for external audiences, are required.
  • Ability to operate effectively in a highly collaborative, cross-functional, and fast-paced biotechnology environment is required.

Responsibilities

  • Provide medical affairs leadership for REM-422 and contribute to development of future programs across the portfolio.
  • Lead development and execution of the Medical Strategy focused on REM-422 for use in adenoid cystic carcinoma.
  • Build scientific awareness of adenoid cystic carcinoma as a MYB-driven disease across medical oncology, head and neck, and ENT communities, and establish the company as a credible scientific voice in the field.
  • Work with stakeholders to map the adenoid cystic carcinoma patient journey, including where patients present, whom they see, how they are referred, and where they leave the care system.
  • Advance understanding of MYB biomarker testing so eligible patients can be identified, partnering with Clinical Development, Regulatory, and diagnostic partners.
  • Generate and codify real-world insight on current management patterns and unmet need, and feed it into development and launch planning.
  • Engage leading adenoid cystic carcinoma, head and neck, and hematology investigators and build the key opinion leader network.
  • Oversee advisory boards, congress strategy, and scientific exchange shaping how adenoid cystic carcinoma is defined and treated.
  • Build durable partnerships with adenoid cystic carcinoma advocacy organizations and bring the patient's voice into development and launch decisions.
  • Represent the company externally in scientific and business development settings.
  • Own publication strategy and execution across adenoid cystic carcinoma and acute myeloid leukemia/myelodysplastic syndromes.
  • Direct health economics and outcomes research, natural history, burden of disease, and real-world evidence work addressing unmet evidence needs for diseases without approved therapy.
  • Run the investigator-sponsored trial program and provide medical insight into company-sponsored trial design, endpoints, and lifecycle strategy.
  • Partner with Clinical Development, Regulatory, and Commercial on launch preparation, contributing the medical and scientific perspective.
  • Ensure the clinical evidence base is accurately understood across the organization so planning reflects what the data supports.
  • Provide independent medical review of educational and promotional material and set the standard for scientific accuracy.
  • Coordinate field medical planning with commercial field planning so coverage is complementary and external interactions are coordinated.
  • Inform market access strategy through burden of disease and health economics evidence.
  • Design and establish field medical, medical information, and medical communications functions; make build-versus-outsource decisions and own the budget.
  • Hire and lead a small, seasoned team and set the plan for scaling the function through approval and launch.
  • Establish medical affairs policies, standard operating procedures, and review processes consistent with scientific engagement principles, partnering with Legal and Compliance to keep activity within company policy and applicable law.
  • Own medical governance of expanded access and compassionate use requests, and the escalation pathway between medical information and Pharmacovigilance.

Desired Qualifications

  • Launch experience is preferred, ideally with a first-in-class or first-in-disease product where the treatment pathway had to be established.
  • A global perspective is preferred, including working knowledge of the European medical affairs and regulatory environment or experience supporting ex-U.S. capability.

About the Company

Remix Therapeutics

Biotech firm developing mRNA-degrading therapies

Remix Therapeutics develops medicines for rare diseases by using targeted degradation of mRNA with an oral small molecule. Its lead candidate REM 422 degrades messenger RNA to stop production of disease-causing proteins and is in Phase 1 trials for ACC and AML, with FDA Orphan Drug designation. The company funds R&D through grants, partnerships, and eventual commercialization, leveraging collaborations with larger pharma. Its goal is to deliver safe and effective medicines for rare cancers and genetic disorders by advancing REM 422 and expanding its portfolio to address unmet medical needs.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Remix Therapeutics

See more jobs